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Abstract: Severe acute respiratory coronavirus-2 syndrome (SARS-CoV-2) is a well-known pandemic
infectious disease caused by an RNA virus belonging to the coronaviridae family. The most important
involvement during the acute phase of infection concerns the respiratory tract and may be fatal.
However, COVID-19 may become a systemic disease with a wide spectrum of manifestations. Herein,
we report the natural history of sacroiliac inflammatory involvement in two females who developed
COVID-19 infection with mild flu-like symptoms. After the infection they reported inflammatory
back pain, with magnetic resonance imaging (MRI) studies showing typical aspects of sacroiliitis.
Symptoms improved with NSAIDs therapy over the following months while MRI remained positive.
A literature review was performed on this emerging topic. To our knowledge, this is the first MRI
longitudinal study of post-COVID-19 sacroiliitis with almost one year of follow-up. Predisposing
factors for the development of articular involvement are unclear but a long-lasting persistence of the
virus, demonstrated by nasopharyngeal swab, may enhance the probability of altering the immune
system in a favourable background.
Keywords: sacroiliitis; arthritis; COVID-19; post-COVID-19 manifestations
1. Introduction
In December 2019, a new type of pneumonia emerged, caused by COVID-19, a mem-
ber of coronaviridae family. The initial outbreak took place in Wuhan, but rapidly diffused
worldwide, such that the World Health Organisation (WHO) declared the disease a pan-
demic in March 2020 [1–4].
Compared to the previous severe acute respiratory syndrome-related coronavirus
(SARS-CoV) and the Middle East respiratory syndrome-related coronavirus (MERS-CoV),
SARS-CoV-2 is much more transmissive and dangerous, with a wide spectrum of systemic
manifestations besides respiratory symptoms [1,2,5,6].
The disease caused by SARS-CoV-2 is often characterised by a dry cough, fever,
dyspnoea, fatigue, general malaise, anosmia, ageusia, a sore throat, diarrhoea, nausea and
vomiting. However, other symptoms have been reported in the literature [1,5–12].
Regarding articular involvement, some cases of arthritis have been described after
SARS-CoV-2 infection, as could happen in other viral diseases, but further studies and
long-term follow-up are required [13–39].
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Articular involvement in COVID-19 can occur in different stages of the disease and it
may be represented by non-specific arthralgia or by acute arthritis. These manifestations
generally respond to non-steroid anti-inflammatory drugs (NSAIDs), but sometimes steroid
treatment is required [15,16,23].
Sometimes patients can develop other musculoskeletal symptoms and signs, such as
enthesitis, tenosynovitis or dactylitis [13–18,20–22,24,27,29–39]; isolated reactive inflamma-
tory sacroiliac involvement after COVID-19 has been rarely recorded.
2. Case Reports
Herein, we report the natural history and long-term follow-up of two cases of sacroili-
itis that developed after COVID-19 infection. They were two females aged 58 and 53, both
working as healthcare professionals in a nursing home with old patients. They devel-
oped SARS-CoV-2 infection in March 2020 after work exposure, and were referred to our
Rheumatologic Clinic for musculoskeletal symptoms such as inflammatory joint pain and
myalgia, which started shortly after SARS-CoV-2 infection.
Demographic/clinical characteristics are illustrated in Table 1, while Table 2 describes
laboratory tests at SARS-CoV-2 infection diagnosis and during the patients’ follow-up.
Finally, complete magnetic resonance imaging (MRI) follow-up is shown in
Figures 1 and 2 for case report 1 and 2, respectively.
Table 1. Demographic and clinical characteristics of the two patients with reactive sacroiliitis post COVID-19 infection.
Feature Patient 1 Patient 2
Age, year 58 53
Gender Female Female
Comorbidity Autoimmune hypothyroidism Autoimmune hypothyroidism
First COVID-related symptoms End of March End of March
First sacroiliitis




End of May End of May
Nasopharyngeal SARS-CoV-2 POSITIVE buffer
(date, month/day) 03/27, 04/04, 04/07, 04/17 03/27, 04/10, 04/17
Nasopharyngeal SARS-CoV-2 NEGATIVE
buffer (date) 04/24, 04/28, 05/12, 05/19 04/24, 04/28, 05/12, 05/19
Drugs for the
infection HCQ and azithromycin HCQ and azithromycin
Treatment of the
sacroiliitis NSAIDs NSAIDs
Clinical outcome Recovery Recovery
First MRI June 2020, bilateralsacroiliitis
June 2020 unilateral
sacroiliitis
Second MRI July 2020, bilateralsacroiliitis
July 2020 unilateral
sacroiliitis
Third MRI January 2021, bilateral sacroiliitis February 2021, unilateral sacroiliitis
Legend: NSAID, non-steroidal anti-inflammatory drug; HCQ, hydroxychloroquine; MRI, magnetic resonance imaging.
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Table 2. Laboratory features at sacroiliitis diagnosis and during follow-up at our centre.
LABORATORY FEATURES
























IgM 0.9 UA/mL ND
Fibrinogen, mg/dL (normal range 180–380) 248 295 250 272 406 247
CRP, mg/L (normal range 0–5.00) 1.20 2.24 1.41 1.49 4.56 2.61
IL1 beta, pg/mL (normal range < 0.001) 0. 0. ND 0. 0 ND
IL6, pg/mL (normal range < 7) 0.9 2 2 1.3 2 2
IL2R, pg/mL (normal range 440–1435) 1346 1446 ND 904 835 ND
IL8, pg/mL (normal range 6.7–16.2) 12.6 13.9 ND 19.2 53 ND
IL10, pg/mL (normal range 1.8–3.8) 1.8 2 ND 2.1 2 ND
TNF alpha, pg/mL (normal range 7.8–12.2) 8.9 13.2 ND 11 66 ND
IFN gamma, pg/mL (normal range < 0.99) 0 1.3 ND 0 0 ND
IP10, pg/mL (normal range 37.2–222) 112 127 ND 90.6 96 ND
Haemoglobin, g/dL 13.7 13.4 13.9 13.8 13.1 13.3
Leucocyte count, cell/mm3 3970 4050 4400 3960 4970 5070
Platelet count, cell/mm3 197,000 223,000 202,000 321,000 305,000 357,000
Antinuclear antibody (ANA) Negative ND Negative Negative ND Negative
Anti-SSA/SSB Negative ND ND Negative ND ND
Rheumatoid factor (RF) Negative ND ND Negative ND ND
CPK, IU/L (normal range 26–170) 187 266 171 101 147 102
Legend: CRP, C-reactive protein; IL, interleukin; IL2R, interleukin 2 receptor; IFN, interferon; TNF, tumour necrosis factor; IP10, human interferon inducible protein 10; CPK, creatine phosphokinase; ND,
not done.
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Figure 1. Case report 1. Persistent MRI findings suggestive of bilateral active sacroiliitis in a 58-year-old patient with lower
back pain. On the first MRI examination, subchondral bone marrow oedema at the iliac side of both sacroiliac joints was
found, appearing as band-like hyperintensity on short-tau-inversion recovery (STIR) T2-weighted semi-coronal image
(arrows in (a)) with corresponding hypointensity on turbo-spin-echo (TSE) T1-weighted semi-coronal image (b). Oedema
was found to persist at a second MRI examination performed one month later (c,d), and increase after six more months (e,f),
especially on STIR T2-weighted image (arrows in (e)).
Figure 2. Case report 2. Persistent MRI findings of unilateral active sacroiliitis in a 53-year-old woman with lower back
pain. At the time of first MRI examination, subchondral bone marrow oedema at the iliac side of the left sacroiliac joint was
observed, appearing as band-like hyperintensity on short-tau-inversion recovery STIR T2-weighted semi-coronal image
(arrow in (a)) with corresponding hypointensity on turbo-spin-echo TSE T1-weighted semi-coronal image (b). Oedema was
found to persist at subsequent MRI examinations performed after one month (c,d) and six months (e,f).
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2.1. Case Report 1
At the end of March 2020, a 58-year-old woman complained of a dry cough without
dyspnoea or fever and tested positive for a SARS-CoV-2-nasopharyngeal swab on March
27. She repeated the nasopharyngeal swab test several times until the first negative result,
which occurred on April 24. Because of persistent positive swabs, she was treated with HCQ
and azithromycin; on May 22 the patient performed a SARS-CoV-2 serological test showing
negative IgM and slightly positive IgG, with limited sensibility and specificity. The patient
suffered from autoimmune hypothyroidism treated with levothyroxine without other
chronic therapy. She had no familiar history for rheumatologic diseases, psoriasis or IBD.
At the end of April, she complained of inflammatory arthralgia and myalgia, especially in
both shoulder and pelvic girdles, and bilateral buttock pain (right > left) with persistent dry
cough. The patient reported that inflammatory pain was slowly and spontaneously improving
from the end of May 2020 in the absence of chronic NSAID administration or other drugs.
At the end of May, upon physical examination she had bilateral sacroiliac joint pain
without peripheral joint tenderness or swelling and no evocable tender points. Chest and
abdominal examinations were normal.
Blood samples showed no inflammation and a mild elevation of CPK.
Extensive laboratory tests were performed, including cytokine profile, which did not
provide further information regarding systemic inflammation (Table 1). Autoantibodies
were negative. The patient presented HLA-B8 and -B57, while HLA-B27 was negative. The
first MRI of shoulders and pelvic girdle (20 June 2020) showed bilateral sacroiliitis with
bone marrow oedema, particularly on the left side (Figure 1a,b). Neither signs of bone
damage nor alterations of the muscles were found.
In July 2020, the repeated MRI showed the same alteration as the first one (Figure 1c,d).
She reported further improvement in articular and muscle pain but persistence of the same
inflammatory back pain and at the clinical examination of sacroiliac joints, tenderness was
still present.
Serological test for SARS-CoV2 was repeated, showing positive IgG and border-
line IgM.
Blood samples were also repeated and no inflammation was found, but a mild eleva-
tion of CPK was confirmed. Serum cytokine profile was substantially normal, showing
only a very mild increase in IL2R and TNF alpha at the second follow-up visit.
Because of sacroiliac joint pain, NSAIDs therapy was started in July for 10 days.
She was evaluated again in November 2020, reporting clinical recovery with only use
of NSAIDs as needed.
MRI was repeated in January 2021 and it showed increased bone marrow oedema of
the sacroiliac joints (Figure 1e,f). On physical examination, the patient still complained
about mild low back pain. She continued to sporadically use NSAIDs, as needed. Blood
tests showed no inflammation and normalisation of CPK.
2.2. Case Report 2
A 53-year-old female, working as a healthcare professional in the same nursing home
as the previous patient, developed a dry cough without fever at the end of March 2020 and
tested positive after repeated SARS-CoV-2 nasopharyngeal swabs (the first on March 27).
She was treated with HCQ and azithromycin with the first negative result of the swab on
April 24. A SARS-CoV-2 serological test performed on May 2020 showed negative IgM and
slightly positive IgG.
In the middle of April, she developed very similar symptoms to her colleague, with a
polymyalgic symptoms associated with inflammatory back pain.
In May, blood tests showed mild systemic inflammation (CRP 19 mg/L, normal values
below 5 mg/L) and CPK elevation (412 IU/L), but they normalised one month later. Serum
cytokine profile revealed only a very mild increase in IL8 at the first follow-up visit.
She stated that these symptoms were gradually and spontaneously improving from
the end of May without any treatment. On clinical examination she had mild tenderness of
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the sacroiliac joints. At the MRI performed on June 3rd, bone marrow oedema suggestive
of sacroiliitis was found (Figure 2a,b). Serologic test for SARS-CoV-2 showed positive IgG
and negative IgM. After blood tests, no inflammation was found, with normalisation of
CRP and CPK. Considering the patient’ symptoms and MRI findings, NSAIDs therapy
was initiated with subjective improvement. She repeated the MRI on July 3rd and it was
unchanged (Figure 2c,d).
At the examination in November 2020, she was using NSAIDs occasionally.
At the follow-up in January 2021 she reported mechanical low back pain and occa-
sional use of NSAIDs, with mild tenderness of the sacroiliac joints upon physical examina-
tion; the MRI performed on February 2021 showed unchanged bone oedema and blood
tests were normal (Figure 2e,f).
3. Materials and Methods
We conducted a PubMed search utilising the keywords “post-COVID-19 arthritis”,
“post-COVID-19 sacroiliitis”, “reactive arthritis”, “reactive sacroiliitis”, “acute sacroiliitis”,
“post-COVID-19 manifestations” and “post-COVID-19 rheumatic diseases”. About one
hundred articles were evaluated and the most relevant were reviewed with more attention;
significant data pertinent to the aim of our study were extracted and organised. In particu-
lar, the most significant articles were represented by reviews concerning reactive arthritis,
post-viral arthritis, acute sacroiliitis and post-COVID-19 rheumatologic manifestations;
case reports about post-COVID-19 arthritis were also considered.
Serum IL-6 (pg/mL) was measured by CE-IVD electrochemiluminescence immunoas-
say (Elecsys IL6, Cobas, Roche, Basel, Switzerland; physiological range < 7 pg/mL). All
other soluble factors were quantified in the same sera of patients with a magnetic bead-
based multiplex assay (Bio-Plex Pro™ Custom Human Cytokines and Chemokine Panel,
procarta-Plex, Bio-Rad Laboratories, Hercules, California) according to the manufacturer’s
instructions. All dosages were obtained in sera stored in aliquots at −80 ◦C.
4. Results
Case reports of supposed SARS-CoV-2-related arthritis are summarised in Table 3
[13–18,20–22,24,27,29–33,36–38].
We also included in our review case reports from Novelli and Baimukhamedov [34,35].
The first described the case of a 27-year-old woman who developed psoriatic spondy-
loarthritis triggered by SARS-CoV-2 infection. The patient developed peripheral arthritis
and mild bilateral sacroiliitis confirmed on MRI; she was HLA-B27 negative and had a
family medical history of psoriasis [34]. Baimukhamedov et al. reported the development
of chronic arthritis, which fulfilled the classification criteria for seropositive rheumatoid
arthritis, one month after COVID-19 infection [35].
Table 3 describes the characteristics of 19 cases, 12 males and 7 females, who were
diagnosed as affected by SARS-CoV-2-related arthritis, without fulfilling the classification
criteria for other arthritis.
The onset of the articular symptoms occurred two to four weeks after the infection
in the majority of cases, while in two cases articular symptoms rose concomitantly to the
diagnosis of COVID-19. The pattern of arthritis was usually mono-oligoarticular, mainly
in the lower limbs (11/19), was polyarticular in 6/19 cases, one case had only extensor
tendonitis of the right hand and another patient developed COVID-19-related dactylitis.
Synovial fluid was negative for crystals. Autoantibodies, rheumatoid factor and antinuclear
antibody were negative in all patients in whom these analyses were performed. HLA B27
was positive in one case.
Imaging study was not available in all patients. Five patients were evaluated by X-rays
which revealed no erosions in all, while five patients were evaluated by ultrasound (US),
which revealed synovitis, and three patients were studied by MRI, which showed signs
of inflammation.
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In some of these cases, synovial fluid analysis was not performed, so we cannot
exclude the presence of crystals. Lopez Gonzalez et al. reported four cases of crystal-
induced arthritis (MSU and CPP crystals detected with polarised light microscopy of the
synovial fluid) during hospitalisation for SARS-CoV-2 infection [23,28].
Alivernini et al. also performed synovial biopsy in two patients, but in one of them an
exacerbation of RA arthritis during SARS-CoV-2 infection was diagnosed, so we did not
include this case [30].
Most of those cases resolved with NSAIDs or with corticosteroids (administered orally
or with intra-articular injection). One case was treated with topical NSAIDs, oral opioid
and gabapentin, one case was treated with baricitinib and corticosteroids and, finally, one
case did not require any treatment.
Sacroiliac joint involvement after COVID-19 infection was reported in three
cases, [34,38,39]; all of them fulfilled the classification criteria for psoriatic arthritis [34], or
HLA-B27-positive axial spondyloarthritis [38,39]. Moreover, in the case report by Coath
et al., COVID-19 infection was not confirmed by nasopharyngeal swab [39].
Notably, the case reported by De Stefano et al. presented transient psoriatic skin
lesions, and in the patient treated by Cincinelli et al., nail psoriasis was previously diag-
nosed [31,37]. However, the authors did not conclude a psoriatic arthritis diagnosis with
sufficient certainty in either case.
Finally, Salvatierra et al. described a case of SARS-CoV-2-related dactylitis in a sixteen-
year-old girl that resolved without NSAIDs [33].
5. Discussion
Articular involvement in SARS-CoV-2 infection may occur at different times, since it
could be an initial symptom of the infection, emerge during the acute phase (sometimes
during hospitalisation) or manifest after recovery.
When it appears during the active phase of the infection, it is generally represented
by non-specific arthralgia, while it could develop into acute arthritis when arising in
the healing period; this feature deviates from classic viral-related arthritis, where joint
involvement usually occurs during the viremia period with acute manifestations of the
infection, as observed by Gasparotto and Ono, and assimilates this clinical manifestation to
post-infectious arthritis [14,18].
The relationship with HLA-B27 positivity did not emerge for COVID-19-related arthri-
tis, while its influence on reactive arthritis is well known.
Since 1999, the term “reactive arthritis” can be applied only to the clinical picture
and the microbes associated with HLA-B27 and spondyloarthritis [40]. Thus, the term
post-COVID-19 sacroiliitis is more appropriate.
Post-COVID-19 arthritis may present with mono- or oligoarticular involvement, with
a predilection for lower limb joints. Generally, it begins some days or a few weeks after
the resolution of other manifestations of the infection [13–18,20–22,24,27,29–33,36–39].
As observed by Di Carlo et al., other possible features of post-viral arthritis are represented
by enthesitis, dactylitis and tenosynovitis [17,33].
Post-COVID-19 arthritis generally responds to NSAIDs, prolonged for 2–4 weeks, like
other viral arthritis. However, steroid treatment is sometimes required, preferably adminis-
tered with intra-articular injection (if there is mono-oligoarticular involvement); in a few cases,
systemic steroid is necessary, but generally for short periods [13–18,20–22,24,27,29–33,36–39].
Only a few cases of SARS-CoV-2-related arthritis required immunosuppressive drugs
(methotrexate and sulphasalazine) [35,38].
Some patients with articular manifestations and severe lung involvement, in the
context of hyperinflammatory syndrome, have been treated with IL-6 inhibitors or with
Jak inhibitors, with significant improvement in both pulmonary and articular manifesta-
tions [30].
While peripheral joint symptoms have been much investigated, axial involvement
related to COVID-19 is still unclear.
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Novelli et al. reported a case of psoriatic spondyloarthritis triggered by SARS-CoV-2
infection and Coath and El Hasbani reported two cases of HLA-B27-positive axial spondy-
loarthritis that emerged closely after COVID-19 [34,38,39].
To our knowledge, our study is the first longitudinal study with MRI in post-COVID-
19 sacroiliitis. Other previous case reports of sacroiliitis documented by MRI after COVID-
19 included cases of seronegative spondyloarthritis, all fulfilling the classification criteria
for psoriatic arthritis or axial spondyloarthritis [34,38,39].
Our patients complained of typical inflammatory lower back pain after the resolution
of infectious symptoms, with clinical features of acute sacroiliitis (insidious onset, night
pain, morning stiffness, improvement with exercise and NSAIDs, radiation to buttocks),
as described after different infections or in the context of reactive arthritis or seronegative
spondyloarthritis [41]; other differential diagnoses were excluded by personal and familiar
history and laboratory tests. Both the patients were negative for HLA-B27. Sacroiliitis was
then confirmed by MRI, that showed bone marrow oedema in typical sites of sacroiliac
joints, and the patients responded well to NSAIDs. Even if it is well known that bone
oedema can be seen in a substantial fraction of healthy people and that our patients could
be at risk for developing lower back pain and even MRI abnormalities due to their work,
the pre-test probability made the MRI findings more likely to be true rather than false
positive [42].
On the other hand, sometimes MRI remains positive after clinical resolution in seroneg-
ative spondyloarthritis [41,43].
Whether persistence of bone marrow oedema represents the persistence of inflam-
matory activity (or its chronicity), or is a result of previous inflammation that requires
more time to disappear, is unclear. Follow-up of those patients is ongoing to monitor both
clinical and imaging evolution.
Generally, imaging findings are not specific, since X-rays are negative and ultrasound
can reveal synovitis, enthesitis or tenosynovitis. Data on MRI are scarce, since only three
other cases have studied sacroiliitis with MRI [34,38,39].
The exact mechanism through which COVID-19 might cause arthropathies is not
completely understood.
Most authors assume the existence of molecular mimicry between viral epitopes and
the synovial membrane causing local inflammation; other theories speculate about the
presence of circulating immune complexes or possible localisation of the virus directly on
joint tissue [14,44].
Interestingly, a mechanism involving molecular mimicry of heat shock proteins/molecular
chaperones, similar to that described in immune adverse events secondary to immunother-
apy for cancer, could be hypothesised. In fact, tumour cells can display on their surface
heat shock proteins/molecular chaperones that are mimicked by SARS-CoV-2 molecules.
Molecular mimicry between SARS-CoV-2 and tumoural proteins can elicit an abnormal
immune reaction by cytotoxic cells against the virus that cross-react with the tumour
cells [45].
In reactive arthritis, chlamydial heat shock protein 60 mimics host self-proteins and
thus can contribute to initiation and maintenance of autoimmune/autoinflammatory dis-
eases [46].
Heat shock proteins have been repeatedly implicated in the pathogenesis of rheuma-
toid arthritis, and increased Hsp27 and Hsp90α mRNA levels have been found in rheuma-
toid arthritis synovial tissues [47,48].
At the moment, the relationship with HLA-B27 positivity is not clear for COVID-19-
related arthritis, while its influence on reactive arthritis is well known [49–51].
Predisposing factors to develop articular involvement consequent to SARS-CoV-2
infection are still unknown, but by evaluating medical literature, it seems that longer
persistence of the virus, as demonstrated by the protracted positivity of nasopharyngeal
swab for SARS-CoV-2, and its spreading from the respiratory tract to other sites including
the gastrointestinal tract, might locally activate immunological and inflammatory pathways
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that could lead to the development of arthritis in some patients, including seronegative
spondyloarthritis, which has been linked to an altered intestinal microbiome [52,53].
Moreover, as described in many studies, SARS-CoV-2 is able to activate in different
ways the immune system; in particular, it can induce interleukin-6 (IL-6)-dependent path-
ways leading to cytokine storm and macrophage activation syndromes; in addition, it
might alter interferon signalling in some cases [19,54–58].
Those altered inflammatory systems may elicit autoimmune processes in predis-
posed individuals.
A mild elevation of some cytokines was identified in our patients; in particular, IL2R,
TNFalpha and IL8, which have been clearly linked both to COVID-19 and inflammatory
arthritis [59].
Despite negativity of specific antibodies and different clinical features, COVID-19
shares similarities with rheumatoid arthritis, in particular regarding the cytokine pattern
involved in the inflammatory process, so inhibitors of these molecules could be used in
selected groups of patients, as used for the treatment of rheumatoid arthritis [19,55,60,61].
Nevertheless, endemic human coronaviruses seem to be associated with an increased risk of
developing rheumatoid arthritis, as described for other viral agents such as parainfluenza
virus and metapneumovirus [62]; therefore, the SARS-CoV-2 pandemic might potentially
lead to increasing cases of rheumatoid arthritis in the near future [63–65].
Hopefully, when an antiviral therapy is available, patients with persistent positivity
of SARS-CoV-2 on nasopharyngeal swab, even if asymptomatic, could be treated to obtain
a faster virus clearance, since the occurrence of post-infectious manifestations may be
decreased by reducing the spread and the exposure of the human immune system to
the virus.
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